ArticlePharmacoEconomics - open2023

The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.

Dawn Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.